

New U.S. Appln. S.N. 10/534,988
AMENDMENT

PATENT

REMARKS


This Amendment places claim 16 in independent form. The animal feature of claim 16 is taken from original (now canceled) claim 1, and is further supported at page 3, line 2. Claims 11-27 are pending.

Applicants provisionally elect Group II, claims 16-22.

Applicants provisionally elect the species of cis-urocanic acid as the pharmaceutical agent, and the species of mastitis as the disease curable by immunosuppression. Claims 16-22 read on the elected species, with claims 16-22 being generic thereto.

It is not believed any fee is required for entry and consideration of this Amendment. Nevertheless, the Commissioner is authorized to charge our Deposit Account No. 50-1258 in the amount of any such required fee.

Respectfully submitted,


James C. Lydon
Reg. No. 30,082

Atty. Case No.: OMAN-002
100 Daingerfield Road
Suite 100
Alexandria, Virginia 22314
Telephone: (703) 838-0445
Facsimile: (703) 838-0447